Addyi Update

By Negar Esfandiari and Kara Cotto  In 2015, Valeant, a pharmaceutical giant known for price gouging and shady business practices paid $1 billion in cash for a flawed sexual enhancement drug marketed to women with so-called “acquired generalized hypoactive sexual desire disorder.” The drug, flibanserin, is sold under the name “Addyi,” and is described as the female version of Viagra. Despite the huge amounts of money involved, the drug’s a bust. It’s crucial for women to understand the small pink … Continued

Keep Passing on the Pink Pill: DON’T “Get Addyi Now”!

By Abby Miller and Susan K. Flinn What do you do when your product isn’t popular and sales have slumped? Gin up an advertising campaign to convince consumers that they absolutely have to have what you’re selling. Flibanserin (brand name “Addyi”) is the first drug approved by the Food and Drug Administration (FDA) to treat so-called “Hypoactive Sexual Desire … Continued

Addyi Health Fact Sheet

  What is Flibanserin (Addyi)? Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.  Although the drug is ineffective and potentially dangerous, the agency approved it in 2015 over the objections of the NWHN and … Continued

Health Advocates Issue One-Year Report Card on Addyi, the Female Libido Drug

FOR IMMEDIATE RELEASE Contact: Shaniqua Seth at or 202.682-2640, ext. 225 WASHINGTON, DC – August 18th marks the one-year anniversary of the Food and Drug Administration’s (FDA) approval of flibanserin (brand name: Addyi), the so-called “female Viagra” pill. In light of recent developments, the National Women’s Health Network (NWHN) has issued a one-year report … Continued

Addyi Report: One Year Later!

One year ago today, the FDA buckled to pressure from a savvy astroturf campaign and approved the female libido drug flibanserin (brand name: Addyi). In response, we launched the “Pass on the Pink Pill – Or Pass Out” campaign to warn women of the marginal benefits and serious side effects of the “pink pill”—complications like … Continued

Addyi 1 Year Later: What’s the Score?

Click image to download PDF of the report card Report Card References 1 – Addyi’s FDA Warning Addyi’s life-threatening side effects were so grave that they warranted the strictest possible warning by the FDA—a “black box warning.” Those side effects include severe, sudden drops in blood pressure that can lead to loss of consciousness for … Continued

Flibanserin Update: Health and Safety Concerns Continue to be Profound

On Monday, JAMA Internal Medicine published a systematic review evaluating the safety and efficacy of flibanserin, a drug purported to treat Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. Unsurprisingly, the researchers reported that flibanserin’s benefits are “are marginal, particularly when taking into account the concurrent occurrence of adverse events.” Further, the researchers reported “the … Continued

This Valentine’s Day, Pop Bottles Not Pills!

Valentine’s Day is right around the corner, and for many us, we are looking for ways to spice things up in the bedroom. As you head to the store to pick up that sexy outfit, bottle of wine, box of chocolates, or even a card for your significant other, be sure to leave the sex … Continued

New Campaign Warns Women of Harm from Drug FDA Approved in August

FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson contact: Sarah Courtney at or 917-913-1994   Feminist Health Advocates Cite Unsafe Sex Drug for Women in Call for Next FDA Commissioner to Resist Political Pressure WASHINGTON, D.C. – As Dr. Robert Califf testifies before the Senate on his nomination for commissioner of the Food and Drug … Continued

Warning of marginal benefits and serious side effects as drug sales begin

FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson and Susan Wood: Sarah Courtney at or 917-913-1994   “PASS ON THE PINK PILL – OR PASS OUT!” Health Advocates Issue Emergency Alert on Addyi:  The New Sex Drug for Women WASHINGTON, DC – The consumer advocacy group National Women’s Health Network (NWHN) today issued its first ever … Continued